Key result
Canagliflozin significantly improved left ventricular diastolic function, reducing the E/e' ratio from 11.3 to 9.1, and enhanced hemodynamic parameters including cardiac index at 24 weeks in patients with type 2 diabetes.
Why the study?
The cardioprotective mechanisms of SGLT2 inhibitors in T2DM remain uncertain, and prior evidence regarding their effects on hemodynamic changes and cardiac remodeling has been conflicting.
Does canagliflozin improve hemodynamic parameters and cardiac remodeling in patients with type 2 diabetes mellitus?
Population
47 patients with T2DM
Comparison
Canagliflozin 100 mg per day added to antidiabetic treatment (baseline vs 24 weeks)
Design
Prospective observational study
Follow-up
24 weeks
Authors
Loading...
Supports mechanistic benefits of canagliflozin on LV function in T2DM; leaves open translation to outcomes without randomized confirmation.
Observational (n=47)
Single-blind
No
Does canagliflozin improve hemodynamic parameters and cardiac remodeling in patients with type 2 diabetes mellitus?
Absolute Event Rate: 9.1% vs 11.3%
p-value: p=<0.001
Canagliflozin improves subclinical left ventricular systolic and diastolic function, as well as systemic hemodynamics, providing mechanistic insight into the cardiovascular benefits of SGLT2 inhibitors in patients with type 2 diabetes.
Kuo et al. (2023) conducted an observational in Type 2 diabetes mellitus (n=47). Canagliflozin vs. Baseline was evaluated on Left ventricular diastolic function assessed by E/e' ratio at 24 weeks (p=<0.001). Canagliflozin significantly improved left ventricular diastolic function, reducing the E/e' ratio from 11.3 to 9.1, and enhanced hemodynamic parameters including cardiac index at 24 weeks in patients with type 2 diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: